AccuStem Sciences Limited (ACMSY) Stock
AccuStem Sciences Limited, founded in 2020 and headquartered in London, United Kingdom, focuses on providing diagnostic assays that utilize genomic signatures. These tests are developed to forecast the probability of both short-term and long-term relapse of ER+/HER2 breast cancer in individuals with an early-stage diagnosis.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About AccuStem Sciences Limited
AccuStem Sciences Limited, founded in 2020 and headquartered in London, United Kingdom, focuses on providing diagnostic assays that utilize genomic signatures. These tests are developed to forecast the probability of both short-term and long-term relapse of ER+/HER2 breast cancer in individuals with an early-stage diagnosis.
the stock is valued at a price-to-earnings (P/E) ratio of -1.08, price-to-book of -0.54, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.12 and $0.13, and currently trades at its 52-week high.
On profitability, AccuStem Sciences Limited generates a return on equity (ROE) of 58533.33% — well above the market average, a sign of a high-quality business, return on capital employed of -113.73%, an operating margin of 0.00%, a net profit margin of 0.00%.
Official website: www.accustem.com